The diagnostics technology developer has raised another $290m from existing investor Roche, which will support it as it looks to expand its products to additional cancers.

Pharmaceutical firm Roche invested $290m in US-based cancer detection technology developer Freenome on Tuesday, roughly a month after it announced its $300m series D round. Founded in 2014, Freenome has developed a multiomics platform which combines molecular biology and machine learning to detect cancer in the early stages through a routine blood draw by decoding…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.